WALTHAM, Mass., July 20, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its second quarter 2017 financial results will be released on Thursday, August 3, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 36834416
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 36834416
A telephone replay will be available from approximately 11:00 a.m. ET on August 3, 2017 through midnight on August 9, 2017.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638


OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Apple Turns 50: From Garage Startup to AI Crossroads
First Western Ship Transits Strait of Hormuz Since Iran War Began
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 



